Condition
EGFR Exon 20 Mutation
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Terminated2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03066206Phase 2TerminatedPrimary
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
NCT04036682Phase 1Active Not Recruiting
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT05241873Phase 1Terminated
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Showing all 3 trials